Bactiguard

First quarter 2025 (January - March)

• Total revenue amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million corresponding to 6.7%.
• Net sales amounted to SEK 59.1 (53.9) million, an increase of SEK 5.1 million corresponding to 9.5%. Adjusted for currency effects of SEK 1.7 million, net sales increased by 6.3%.
• Operating loss amounted to SEK 2.6 (12.9) million.
• EBITDA amounted to SEK 9.4 (-1.5) million.
• Net loss for the period amounted to SEK 4.7 (9.9) million.
• Loss per share, before and after dilution, amounted to SEK 0.13 (0.28).
• Cash flow from operating activities amounted to SEK -12.1 (-19.1) million corresponding to SEK -0.35 (-0.54)

Christine Lind, CEO of Bactiguard comments:

"Following the 2024 financial turnaround, we continue our profitable path with yet another strong quarter. EBITDA amounted to SEK 9.4 million (Q1 2024: SEK -1.5 million) and revenues increased by 6.7 percent compared to Q1 last year and landed at SEK 62.7 million (Q1 2024: SEK 58.8 million). Our license business developed well, primarily driven by the successful collaboration with license partner BD, demonstrating a consistent positive financial performance thanks to our strategic transition. The Wound Management portfolio also had a strong quarter with a revenue increase of more than 50 percent, fueled by a significant rise in sales of Hydrocyn aqua. During the quarter, we also updated our strategic and financial targets and core therapeutic areas, areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device related infections."

Bactiguard Holding AB's (publ) report for the first quarter 2025 is available at https://ir.bactiguard.com/